ReviewClinical advances in hematology & oncology : H&O2013
Targeting bone physiology for the treatment of metastatic prostate cancer.
Review in Clinical advances in hematology & oncology : H&O, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- The Tight Relationship Between the Tumoral Microenvironment and Radium-223.Biomedicines · 2025Review
- Primary and Metastatic Bone Tumors of the Patella: Literature Review and Institutional Experience.The archives of bone and joint surgery · 2022Review
- Current concepts in bone metastasis, contemporary therapeutic strategies and ongoing clinical trials.Journal of experimental & clinical cancer research : CR · 2017Review
- The Role of the Microenvironment in Prostate Cancer-Associated Bone Disease.Current osteoporosis reports · 2016Review
- Radiotherapy cannot prolong overall survival of young prostate cancer patients with bone metastases.Journal of translational medicine · 2016Article
- Osteoclast derivation from mouse bone marrow.Journal of visualized experiments : JoVE · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Metastatic prostate cancer has a unique predilection for bone that can lead to significant clinical sequelae, such as fracture and cord compression. This tropism for bone yields not only clinical challenges, but also opportunities to understand the tumor biology in bone and to develop relevant therapeutic strategies. The process by which tumor cells migrate to bone, remain dormant, and then colonize and expand is based on complex interactions between prostate cancer tumor cells and the host microenvironment. This review will provide an overview of these interactions as well as therapies targeting osseous metastases in castration-resistant prostate cancer.
Indexed as
Identifiers
23598981PMC3938391What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.